Mangrove Partners IM LLC bought a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 10,587 shares of the specialty pharmaceutical company’s stock, valued at approximately $836,000.
Several other hedge funds have also recently made changes to their positions in ANIP. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at about $28,000. Hantz Financial Services Inc. raised its position in shares of ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after buying an additional 249 shares in the last quarter. State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $50,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of ANI Pharmaceuticals by 30.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock valued at $86,000 after buying an additional 253 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of ANI Pharmaceuticals by 542.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,727 shares of the specialty pharmaceutical company’s stock valued at $113,000 after buying an additional 1,458 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.
ANI Pharmaceuticals Stock Performance
Shares of NASDAQ:ANIP opened at $83.00 on Wednesday. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of 21.01 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 12 month low of $62.60 and a 12 month high of $99.50. The firm’s 50-day moving average is $80.06 and its 200 day moving average is $79.40. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06.
Wall Street Analyst Weigh In
ANIP has been the topic of several recent research reports. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, June 1st. Finally, Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $107.33.
Check Out Our Latest Stock Analysis on ANI Pharmaceuticals
Insider Activity at ANI Pharmaceuticals
In related news, Director Thomas Haughey sold 2,000 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.88, for a total transaction of $161,760.00. Following the transaction, the director directly owned 38,878 shares in the company, valued at approximately $3,144,452.64. This represents a 4.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nikhil Lalwani sold 55,000 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $77.57, for a total transaction of $4,266,350.00. Following the completion of the transaction, the chief executive officer owned 349,889 shares in the company, valued at $27,140,889.73. This represents a 13.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 79,016 shares of company stock worth $6,195,991 in the last three months. 8.10% of the stock is owned by insiders.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Read More
- Five stocks we like better than ANI Pharmaceuticals
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
